Grail, Inc.(US:GRAL) Yahoo Finance·2026-01-02 08:28Group 1 - Grail Inc. (NASDAQ:GRAL) experienced a significant increase of 379.5 percent in 2025, driven by positive analyst ratings and confidence in its early cancer detection test kit, Galleri [1] - Galleri is a single blood test designed to screen over 50 types of cancer, with a reported positive predictive value of 61.6 percent from its Pathfinder 2 clinical study [1] - Samsung group has backed Grail Inc. for the exclusive distribution of Galleri in South Korea and other key Asian markets, acquiring a $110 million stake at a price of $70.05 per share [2] Group 2 - Analysts have shown optimism towards Grail Inc., with Canaccord issuing a "buy" recommendation and raising its price target to $105, while Morgan Stanley increased its target to $110, maintaining an "equal weight" rating [2] - Grail Inc. plans to seek FDA pre-market approval for Galleri within the first quarter of 2026 [2]